This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
by Zacks Equity Research
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
ALNYPositive Net Change BMRNNegative Net Change AVXLNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
BEAMPositive Net Change VYGRPositive Net Change CSTLPositive Net Change HRMYNegative Net Change
biotechs
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
by Zacks Equity Research
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
JAZZNegative Net Change VYGRPositive Net Change AXSMNegative Net Change CSTLPositive Net Change
biotechs
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
by Zacks Equity Research
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
BIIBNegative Net Change NVOPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
by Zacks Equity Research
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
NVSPositive Net Change BIIBNegative Net Change RHHBYPositive Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy launch progresses.
VRTXNegative Net Change MRNANegative Net Change CRSPPositive Net Change
biotechs
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
by Zacks Equity Research
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
BMRNNegative Net Change CYTKPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
by Zacks Equity Research
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
BMRNNegative Net Change CTMXNegative Net Change CSTLPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
REGNPositive Net Change VYGRPositive Net Change NTLANegative Net Change CSTLPositive Net Change
biotechs
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
SNYPositive Net Change BMYNegative Net Change JNJPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
by Zacks Equity Research
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.
BMYNegative Net Change VYGRPositive Net Change REPLPositive Net Change CSTLPositive Net Change
biotechs
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
by Zacks Equity Research
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
JNJPositive Net Change BMRNNegative Net Change CSTLPositive Net Change NBTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
by Zacks Equity Research
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
GSKPositive Net Change VYGRPositive Net Change ANABNegative Net Change CSTLPositive Net Change
biotechs
Denali Gains 26.6% in a Year: How Should You Play the Stock?
by Zacks Equity Research
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs pharmaceuticals
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
GSKPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AZNPositive Net Change CTMXNegative Net Change CSTLPositive Net Change ERASNegative Net Change
biotechs medical pharmaceuticals vaccines
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
BMRNNegative Net Change NVOPositive Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
by Zacks Equity Research
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
AMGNPositive Net Change VYGRPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
by Zacks Equity Research
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
MRNANegative Net Change NVAXPositive Net Change CVACPositive Net Change
biotechs medical messenger-rna vaccines
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
REGNPositive Net Change IONSNegative Net Change NTLANegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
GSKPositive Net Change PFENegative Net Change MRKPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
VYGRPositive Net Change CTMXNegative Net Change STOKPositive Net Change CSTLPositive Net Change
biotechs
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
by Zacks Equity Research
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
BMRNNegative Net Change CTMXNegative Net Change CSTLPositive Net Change IBRXNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals